Browsing Tag
Atossa Therapeutics
2 posts
Atossa Therapeutics (NASDAQ: ATOS) deepens Z-endoxifen bet as 2025 losses widen and rare disease optionality grows
Atossa Therapeutics widened its 2025 loss as Z-endoxifen spending rose and rare disease optionality expanded. Read what this could mean for ATOS.
Atossa Therapeutics (Nasdaq: ATOS) gains FDA orphan drug designation for (Z)-endoxifen in Duchenne muscular dystrophy
Find out how Atossa Therapeutics’ orphan drug nod for (Z)-endoxifen in Duchenne muscular dystrophy could reshape its R&D roadmap.